Medically treated prolactin-secreting pituitary adenomas: when should we operate?

References

• Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol 2001;54:139–50.
   PubMed Web of Science ®Google Scholar
• Vance ML, Thorner MO. Prolactinomas. Endocrinol Metab Clin North Am 1987;16:731–53.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 1992;21:877–901.
   PubMed Web of Science ®Google Scholar
• Kreutzer J, Buslei R, Wallaschofski, . Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 2008;158:11–18.
   PubMed Web of Science ®Google Scholar
• Hamilton DK, Vance ML, Boulos P, Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005;8:53–60.
   PubMedGoogle Scholar
• Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999;44: 254–63.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002;5:55–65.
   PubMedGoogle Scholar
• Landolt AM, Osterwalder V. Perivascular fibrosis in prolactinomas: is it increased by bromocriptine. J Clin Endocrinol Metab 1984;58:1179–83.
   PubMed Web of Science ®Google Scholar
• Bevan JS, Adams C, Burke CW, . Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy. Clin Endocrinol 1987;26:541–56.
   PubMed Web of Science ®Google Scholar
• Landolt AM, Keller PJ, Froesch ER, Mueller J. Bromocriptine: does it jeopardise the result of later surgery for prolactinomas. Lancet 1982;2:657–8.
   PubMed Web of Science ®Google Scholar
• Landolt AM. Prolactinomas: Preoperative Bromocriptine Treatment, Vol. 1. St Louis: Quality Medical Publishing, 1990.
   Google Scholar
• Melkersson K, Hulting AL. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder. Eur Arch Psychiatry Clin Neurosci 2000;250:6–10.
   PubMed Web of Science ®Google Scholar
• Casanueva FF, Molitch ME, Schlechte JA, . Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265–73.
   PubMed Web of Science ®Google Scholar
• Kreutzer J, Buslei R, Wallaschofski H, . Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 2008;158:11–8.
   PubMed Web of Science ®Google Scholar
• Hildebrandt G, Zierski J, Christophis P, . Rhinorrhea following dopamine agonist therapy of invasive macroprolactinoma. Acta Neurochir (Wien) 1989;96:107–113.
   PubMed Web of Science ®Google Scholar
• Holness RO, Shlossberg AH, Heffernan LP. Cerebrospinal fluid rhinorrhea caused by bromocriptine therapy of prolactinoma. Neurology 1984;34:111–13.
   PubMed Web of Science ®Google Scholar
• D’Haens J, Van Rompaey K, Stadnik T, Haentjens P, Poppe K, Velkeniers B. Fully endoscopic transsphenoidal surgery for functioning pituitary adenomas. A retrospective comparison with traditional transsphenoidal microsurgery in the same institution. Surg Neurol 2009;72:336–40.
   PubMedGoogle Scholar
• Ciccarelli E, Giusti M, Miola C, . Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725–8.
   PubMed Web of Science ®Google Scholar
• Ferrari C, Mattei A, Melis GB, . Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201–6.
   PubMed Web of Science ®Google Scholar
• Ferrari C, Paracchi A, Mattei A, de Vincentiis S, D’Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 1992;126: 489–94.
   PubMedGoogle Scholar
• Ferrari C, Paracchi A, Romano C, . Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol 1988;29:467–76.
   PubMed Web of Science ®Google Scholar
• Webster J, Piscitelli G, Polli A, Ferrari C, Ismail I, Scanlon M. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904–9.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Landi M, . Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2247–52.
   PubMed Web of Science ®Google Scholar
• Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 1986;10: 172–95.
   PubMed Web of Science ®Google Scholar
• Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006;125: 152–64.
   PubMed Web of Science ®Google Scholar
• Aubourg PR, Derome PJ, Peillon F, . Endocrine outcome after transsphenoidal adenomectomy for prolactinoma:prolactin levels and tumor size as predicting factors. Surg Neurol 1980;14:141–3.
   PubMedGoogle Scholar
• Hardy J. Secretory Tumors of Pituitary Gland, Vol. 1. New York: Raven Press, 1984.
   Google Scholar
• Raverot G, Wierinckx A, Dantony E, . Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 2010;95:1708–16.
   PubMed Web of Science ®Google Scholar
• Ono M, Miki N, Kawamata T, . Prospective study of high dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008;93:4721–7.
   PubMed Web of Science ®Google Scholar
• Horvath J, Fross RD, Kleiner-Fisman G, . Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656–62.
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29–38.
   PubMed Web of Science ®Google Scholar
• Molitch ME. The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 2008;93:4643–5.
   PubMed Web of Science ®Google Scholar